October 23, 2017 6:08 AM ET

Biotechnology

Company Overview of Edge Therapeutics, Inc.

Company Overview

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

300 Connell Drive

Suite 4000

Berkeley Heights, NJ 07922

United States

Founded in 2009

31 Employees

Phone:

800-208-3343

Fax:

908-790-1212

Key Executives for Edge Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $467.5K
Co-Founder, Chief Scientific Officer and Director
Age: 55
Total Annual Compensation: $390.0K
Chief Medical Officer
Age: 64
Total Annual Compensation: $337.1K
Compensation as of Fiscal Year 2016.

Edge Therapeutics, Inc. Key Developments

Edge Therapeutics, Inc. Presents at 5th Annual Promotional Review Committee Compliance & Best Practices conference, Oct-16-2017 03:40 PM

Edge Therapeutics, Inc. Presents at 5th Annual Promotional Review Committee Compliance & Best Practices conference, Oct-16-2017 03:40 PM. Venue: Wyndham Hamilton Park, Florham Park, New Jersey, United States. Speakers: Howard Dorfman, Senior Corporate Counsel.

Edge Therapeutics, Inc. Presents at LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology, Sep-27-2017 01:30 PM

Edge Therapeutics, Inc. Presents at LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology, Sep-27-2017 01:30 PM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Brian A. Leuthner, Co-Founder, Chief Executive Officer, President and Director.

Edge Therapeutics, Inc. Appoints Rosemary A. Crane as Board of Director

Edge Therapeutics, Inc. announced the appointment of Rosemary A. (Rose) Crane to the company’s board of directors. Ms. Crane currently serves as a Director of Teva Pharmaceuticals and as Vice Chairman of the Board of Zealand Pharma A/S.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Edge Therapeutics, Inc., please visit www.edgetherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.